Management of Retinitis Pigmentosa

Search on blog

Latest blog posts

PRP in Urology: Clinical Applications and Injection Protocols

PRP: Preparation Protocol, Indications and Clinical Applications

PRP and Abdominoplasty: Wound Healing and Post-Operative Recovery

PRP and Knee Pathologies: Indications and Injection Protocol

Osteoarthritis of the Knee: PRP or Hyaluronic Acid - Which Option is Better?

See all

Our prp products online

Top Sellers

PRF CGF Silfradent CE dry tube - MDR certified

€5.00

Presentation of the contents of the two PRP tubes

2 Tlab PRP tubes with anticoagulant

€32.00

Kit 2 PRP Xenoderm 10ml tubes with anticoagulant and separator gel

€37.00

Published : 03/22/2021

Table of contents

Introduction
Methods
Results
Conclusions

Introduction

Translation of the article published in Research Square in 2020

Management of retinitis pigmentosa with platelet-rich plasma or in combination with electromagnetic stimulation: one-year retrospective analysis of outcomes.

Methods

The study includes an analysis of 60 patients with retinitis pigmentosa divided into 3 groups with similar demographic characteristics:

Group 1 (20 patients, 40 eyes): combined retinal electromagnetic stimulation + subtenon autologous PRP
Group 2 (20 patients, 40 eyes): subtenon PRP only
Group 3 (20 patients, 40 eyes): no treatment (control group)

Horizontal and vertical ellipsoid zone width, deviation index of fundus perimetry and best-corrected visual acuity changes were compared within and between groups after one year of follow-up.

Results

Percentage changes in horizontal ellipsoid zone: +1% in Group 1, -2.85% in Group 2, -9.36% in Group 3 (Δp 1 > 2 > 3). Vertical ellipsoid zone: +0.34% in Group 1, -3.05% in Group 2, -9.09% in Group 3. Fundus perimetry deviation index: +0.05% in Group 1, -2.68% in Group 2, -8.78% in Group 3 (Δp 1 > 2 > 3).

Conclusions

Platelet-rich plasma is a good source of growth factors, but its half-life is 4 to 6 months. Autologous subtenon PRP may more effectively slow down photoreceptor loss when repeated as booster injections and combined with retinal electromagnetic stimulation.